Autophagy Modulation | Agent | Effects | Related Disease | References |
---|---|---|---|---|
Activation | Rapamycin | Prevents thyroid hormone, aortic banding, or pressure overload-induced cardiac hypertrophy | Cardiac hypertrophy | Nishida et al., 2009 |
Sulfaphenazole | Protects cardiomyocytes against I/R in vitro and in vivo | Heart disease | Huang et al., 2010 | |
Chloramphenicol succinate | Reduces myocardial damage during I/R | Heart disease | Sala-Mercado et al., 2010 | |
Everolimus | Selectively clears macrophagy and protects smooth muscle cells | Atherosclerosis | Verheye et al., 2007 | |
Inhibition | Trichostatin A | Blunts pathologic cardiac remodeling during severe pressure overload | Heart disease | Cao et al., 2011 |
Propofol | Limits myocardial damage during I/R in vivo | Heart disease | Noh et al., 2010 | |
G-CSF | Reduces myocardial fibrosis and improves hamster survival | Cardiomyopathy | Miyata et al., 2006 | |
Urocortin | Reduces myocyte cell death | Heart disease | Valentim et al., 2006 | |
Activation | Rapamycin | Promotes CD8+ T cell memory formation | Infectious disease | |
AR-12 | Inhibits the survival of bacteria in human and murine macrophages | Infectious disease | Chiu et al., 2009a,b | |
1,25D3 | Inhibits HIV replication and mycobacterial growth | Infectious disease | Campbell and Spector, 2012 | |
Activation | Isoniazid or pyrazinamide | Dampens M. tuberculosis–induced proinflammatory responses in macrophagy | Infectious disease | Kim et al., 2012 |
Activation | Rapamycin | Clears expanded polyQ and mutant huntingtin, and reduces their toxicity in vitro and in vivo | Huntington disease | Berger et al., 2006; Ravikumar et al., 2002, 2004 |
Small-molecule enhancers of rapamycin | Enhances the clearance of mutant huntingtin and α-synuclein | Huntington and Parkinson disease | Sarkar et al., 2007b | |
Rapamycin | Increases the clearance of α-synuclein | Parkinson disease | Webb et al., 2003 | |
Lithium and trehalose | Promotes the clearance of mutant huntingtin and α-synuclein | Huntington and Parkinson disease | Sarkar et al., 2007a, 2005 | |
l-NAME | Enhances the degradation of huntingtin | Huntington disease | Sarkar et al., 2011 | |
Activation | Rapamycin or methionine sulfoximine | Increases the chronologic life span in S. cerevisiae | Aging | Powers et al., 2006 |
l-NAME, NG-nitro-l-arginine methyl ester.